



## Food and Drug Administration Advisory Committee Member Acknowledgment of Financial Interests

Name of Advisory Committee Member: Matthew J. Eagleton, M.D.

Committee: Circulatory System Devices Panel of the Medical Devices Advisory Committee

Meeting Dates: November 3, 2021

I acknowledge that contingent upon public disclosure of the following financial interest(s) related to the agenda item to discuss and make recommendations on the continued safety and effectiveness of endovascular stent grafts, I may be considered for participation in the advisory committee meeting described above.

<u>Type of Interest</u>	<u>Nature</u>	<u>Magnitude</u>
<b>I. Personal/Immediate Family</b>		
None		
<b>II. Other Imputed Interests</b>		
Employer's grant	SGE's institution involved in competitor's product study	\$50,001 – 100,000

I hereby request that FDA make this information publicly available on my behalf if the agency grants a waiver allowing me to participate in the meeting described above. I understand that without public disclosure of these interests, I will not participate in the advisory committee meeting described above.

\_\_\_\_\_/S/\_\_\_\_\_  
Signature

\_\_\_\_\_**October 7, 2021**\_\_\_\_\_  
Date